Related Experiment Video
Updated: Apr 19, 2026

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
Published on: March 23, 2022
Castleman disease - one name, many faces
Insights
Castleman disease is a lymph node disorder with varied causes and presentations. Diagnosis and treatment depend on subtype, ranging from surgery for unicentric forms to complex therapies for multicentric Castleman disease.
Area of Science:
- Hematology
- Pathology
- Oncology
Background:
- Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders.
- Morphologically, CD is classified into hyaline-vascular, plasmacytic, and mixed types.
- Diagnosis requires integrating clinical criteria with pathological findings.
Purpose of the Study:
- To provide a comprehensive overview of Castleman disease.
- To describe the morphological changes and clinical characteristics of CD subtypes.
- To highlight the diagnostic and therapeutic complexities of CD.
Main Methods:
- Review of current literature and clinical guidelines.
- Analysis of morphological classifications (hyaline-vascular, plasmacytic, mixed).
- Correlation of clinical presentations with disease subtypes (unicentric, multicentric).
Main Results:
- Unicentric CD typically involves a single lymph node, often curable by surgery.
- Multicentric CD affects multiple lymph nodes, presenting with systemic symptoms.
- Multicentric CD subtypes include idiopathic (TAFRO syndrome, plasmacytic lymphadenopathy) and HHV-8/POEMS-associated forms.
Conclusions:
- Castleman disease diagnosis and management are complex, requiring multidisciplinary collaboration.
- Treatment strategies for multicentric CD are etiological and may involve biological agents, chemotherapy, or IL-6 inhibition.
- Accurate subtyping is crucial for effective treatment of Castleman disease.
Abstract:
Castleman disease (CD) is a mesmerising group of disorders mainly affecting lymph nodes sharing some morphological features but with heterogeneous aetiology, clinical presentation and therapeutic approaches. Morphologically, hyaline-vascular (or hypervascular), plasmacytic, and mixed types of changes are distinguished. Confirmation of the diagnosis and subtype of Castleman disease involves meeting or excluding several clinical criteria and therefore requires close cooperation with a clinician. Unicentric Castleman disease involves usually a solitary enlarged lymph node with mild symptoms and excision surgery is often curative. Multicentric forms of Castleman disease affect multiple groups of lymph nodes and are associated with varying degrees of systemic clinical symptoms. Multicentric Castleman disease is either idiopathic or associated with human herpesvirus 8 infection or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes). Idiopathic multicentric Castleman disease is further divided into a variant associated with TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis / renal dysfunction, and organomegaly), idiopathic plasmacytic lymphadenopathy type, and not otherwise specified variant. The treatment of multicentric forms of Castleman disease is complex and depends on etiological factors, including biological therapy, chemotherapy, or interleukin-6 activity inhibition. The aim of this educational text is to present the current view of Castleman disease and provide a comprehensive description of the morphological changes and clinical characteristics of the individual subtypes of Castleman disease.
More Related Videos
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
07:50A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Huntington Disease l: Introduction
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cirrhosis I: Introduction